Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...
That's because CRISPR Therapeutics soon will generate revenue from Casgevy, and this biotech also has a full pipeline of ...
The Motley Fool on MSN13d
2 Magnificent Stocks to Buy That Are Near Their 52-Week LowsSome investors believe you make money when you buy a stock, not when you sell it ... provided there are good reasons to ...
Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...
CRISPR's current valuation is attractive, with $1.9 billion in cash and expected revenue from Casgevy, making it a speculative but compelling buy. Editas and CRISPR are probably most closely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback